NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

June 28, 2022

Study Completion Date

July 8, 2022

Conditions

2019 Novel Coronavirus Disease2019 Novel Coronavirus Infection2019-nCoV Disease2019-nCoV InfectionCOVID-19COVID-19 PandemicCOVID-19 Virus DiseaseCOVID-19 Virus InfectionCovid19Coronavirus Disease 2019SARS-CoV2 InfectionSARS-CoV-2 Acute Respiratory Disease

Interventions

DRUG

Famotidine

80 mg tablet, QID for 14 days

DRUG

Celecoxib

400 mg (initial dose), then 200 mg capsule, BID for 5 days

DRUG

Placebo

tablet, QID for 14 days; capsule, BID for 5 days

Trial Locations (15)

10005

Integrated Therapeutic Solutions USA, Inc., New York

16652

Integrated Therapeutic Solutions USA, Inc., Huntingdon

20850

Integrated Therapeutic Solutions USA, Inc, Rockville

20878

Integrated Therapeutic Solutions USA, Inc, Gaithersburg

21702

Integrated Therapeutic Solutions USA, Inc, Frederick

29414

Integrated Therapeutic Solutions USA, Inc., Charleston

30363

Integrated Health Solutions USA, Inc., Atlanta

31539

Integrated Therapeutic Solutions USA, Inc, Hazlehurst

33126

Integrated Therapeutic Solutions USA, Inc., Miami

40059

Integrated Therapeutic Solutions USA, Inc, Prospect

48120

Integrated Therapeutic Solutions USA, Inc, Dearborn

60611

Integrated Therapeutic Solutions USA, Inc., Chicago

75219

Integrated Therapeutic Solutions USA, Inc., Dallas

92603

Integrated Therapeutic Solutions USA, Inc., Newport Beach

07102

Integrated Therapeutic Solutions USA, Inc., Newark